Mutagenic and Genotoxic Effects of <Emphasis Type="Italic">cis</Emphasis>-(Dichloro)tetraammineruthenium(III) Chloride on Human Peripheral Blood Lymphocytes

Chemotherapeutic agents play an important role in cancer treatment mostly due their systemic action on human organism allowing access to liquid tumors and even metastases. Among these drugs, ruthenium compounds have been showing promising results to treat tumors and represent an important development of new antitumor therapy. This study presents the evaluation of cis-(dichloro)tetraammineruthenium(III) chloride, cis-[RuCl₂(NH₃)₄]Cl, genotoxic effects using human peripheral blood lymphocytes cultured in vitro. Mitotic index (MI), chromosome aberrations (CA), and DNA damage using the comet assay were analyzed. MI in human peripheral blood lymphocyte cultures treated with 1, 10, 100, and 1,000 μg mL⁻¹ cis-[RuCl₂(NH₃)₄]Cl were 5.9%, 4.6%, 3.9%, and 0%, respectively. Doxorubicin chloridate was used as the positive control. CA derived from 1, 10, and 100 μg mL⁻¹ concentrations were defined as spontaneous when compared with the negative control, and at the concentration of 1,000 μg mL⁻¹, the cell cycle was inhibited (IM = 0%). Results obtained for the comet assay using cis-[RuCl₂(NH₃)₄]Cl suggest that this compound has no genotoxic activity against cultured human peripheral blood lymphocytes.     

The Ruthenium Complex cis-(Dichloro)tetraammineruthenium(III) Chloride Presents Selective Cytotoxicity Against Murine B Cell Lymphoma (A-20), Murine Ascitic Sarcoma 180 (S-180), Human Breast Adenocarcinoma (SK-BR-3), and Human T Cell Leukemia (Jurkat) Tumor Cell Lines

The aim of present study was to verify the in vitro antitumor activity of a ruthenium complex, cis-(dichloro)tetraammineruthenium(III) chloride (cis-[RuCl₂(NH₃)₄]Cl) toward different tumor cell lines. The antitumor studies showed that ruthenium(III) complex presents a relevant cytotoxic activity against murine B cell lymphoma (A-20), murine ascitic sarcoma 180 (S-180), human breast adenocarcinoma (SK-BR-3), and human T cell leukemia (Jurkat) cell lines and a very low cytotoxicity toward human peripheral blood mononuclear cells. The ruthenium(III) complex decreased the fraction of tumor cells in G0/G1 and/or G2-M phases, indicating that this compound may act on resting/early entering G0/G1 cells and/or precycling G2-M cells. The cytotoxic activity of a high concentration (2 mg mL^?1) of cis-[RuCl₂(NH₃)₄]Cl toward Jurkat cells correlated with an increased number of annexin V-positive cells and also the presence of DNA fragmentation, suggesting that this compound induces apoptosis in tumor cells. The development of new antineoplastic medications demands adequate knowledge in order to avoid inefficient or toxic treatments. Thus, a mechanistic understanding of how metal complexes achieve their activities is crucial to their clinical success and to the rational design of new compounds with improved potency.     

Cytotoxic and Genotoxic Effects of <Emphasis Type="Italic">cis</Emphasis>-Tetraammine(oxalato)Ruthenium(III) Dithionate on the Root Meristem Cells of <Emphasis Type="Italic">Allium cepa</Emphasis>

Ruthenium complexes have attracted much attention as possible building blocks for new transition-metal-based antitumor agents. The present study examines the mitotoxic and clastogenic effects induced in the root tips of Allium cepa by cis-tetraammine(oxalato)ruthenium(III) dithionate {cis-[Ru(C₂O₂)(NH₃)₄]₂(S₂O₆)} at different exposure durations and concentrations. Correlation tests were performed to determine the effects of the time of exposure and concentration of ruthenium complex on mitotic index (MI) and mitotic aberration index. A comparison of MI results of cis-[Ru(C₂O₂)(NH₃)₄]₂(S₂O₆) to those of lead nitrate reveals that the ruthenium complex demonstrates an average mitotic inhibition eightfold higher than lead, with the frequency of cellular abnormalities almost fourfold lower and mitotic aberration threefold lower. A. cepa root cells exposed to a range of ruthenium complex concentrations did not display significant clastogenic effects. Cis-tetraammine(oxalato)ruthenium(III) dithionate therefore exhibits a remarkable capacity to inhibit mitosis, perhaps by inhibiting DNA synthesis or blocking the cell cycle in the G2 phase. Further investigation of the mechanisms of action of this ruthenium complex will be important to define its clinical potential and to contribute to a novel and rational approach to developing a new metal-based drug with antitumor properties complementary to those exhibited by the drugs already in clinical use.     

Synthesis of ruthenium(II) monosubstituted squarates: 1. Procedural considerations

Attempted syntheses of ruthenium(II) monosubstituted squarate complexes in acetonitrile using cis-[RuCl₂(dmso)₄] and anisole-, methoxy-, methyl- and diphenylamino-squarate ligands, respectively, resulted in the formation in each case of the monomer cis, fac-Ru(CH₃CN)Cl₂(dmso)₃ (1) with the ruthenium atom in a distorted octahedral environment. A second crop of crystals harvested from the reaction with the methoxysquarate ligand was identified as the oxalato-bridged dimer [{cis-(CH₃CN)(Cl)(dmso)₂Ru}₂(μ-C₂O₄)] (2). When cis-[RuCl₂(dmso)₄] and methylsquarate were reacted in aqueous solution instead of acetonitrile, the dimer [{fac-(Cl)(dmso)₃Ru}₂(μ-C₂O₄)] (3) was produced. The dimers 2 and 3 are formed from oxidation/ring opening of the methoxy- and methyl-squarate ligands, respectively. Use of the salts of these ligands instead of their non-ionised forms under different reaction conditions, afforded [Na] fac-[RuCl₃(dmso)₃] (4) and [(C₄H₉)₄N]₂[(C₄O₄)(C₄H₂O₄)₂] (7), respectively, which were shown to be products of competing reactions. The information acquired from these failed attempts has provided the basis for the development of a strategy to overcome these problems and lead to a successful synthetic route to ruthenium(II) monosubstituted squarates.     

Ruthenium-modified proteins. Reactions of cis-[ Ru(NH3)4(OH2)2]2+ and cis-[ Ru(en)2(OH2)2]2+ with azurin,myoglobin and cytochrome c

Reactions of cis-[Ru(en)₂(OH₂)₂]²⁺ (or cis-[Ru (NH₃)₄(OH₂)₂]²⁺) with Pseudomonas aeruginosa azurin (Az), horse heart myoglobin (Mb^h), and horse heart cytochrome c (cyt c) give Ru-labelled proteins. The ruthenium binding sites in the singly modified derivatives are His-83 (Az), His-81 (Mb^h), and His-33 (cyt c). Spectroscopic and electrochemical measurements indicate that the structures of the proteins are not perturbed by the surface-bound ruthenium complexes. The E°_f values of the Ru(III)/(II) couple in these Ru-modified proteins fall between −0.07 and −0.13 V vs. NHE.     

Mutagenic activity of platinum and ruthenium complexes

cis-Dichlorodiammineplatinum(II) [cis-PtCl₂(NH₃)₂] and dichlorotetrakis (dimethylsulfoxide) ruthenium(II) [RuCl₂(DMSO)₄] have been tested as mutagens for strains of Salmonella typhimurium carrying the hisG46 missense mutation. Their activity, which has been compared with the activity of mitomycin C, depends on the presence in the test bacteria of the pKM101 plasmid and is affected in various ways by the function of the excision repair system. More precisely, mitomycin C is mutagenic only for strains with an intact uvr system. cisPtCl₂(NH₃)₂ and RuCl₂(DMSO)₄ are mutagens both for uvrB and uvr⁺ strains, but cis-PtCl₂(NH₃)₂ is more active on the latter, while the converse is true for RuCl₂(DMSO)₄. It seems, therefore, that each drug interacts with DNA by a different mechanism.     

Platinum(II) triammine antitumour complexes: structure-activity relationship with guanosine 5′-monophosphate (5′-GMP)

The multinuclear (¹H, ¹⁵N, ³¹P and ¹⁹⁵Pt) NMR spectroscopies, ES-MS and HPLC have been employed to investigate the structure-activity relationship for the reactions between guanosine 5′-monophosphate (5′-GMP) and the platinum(II)-triamine complexes of the general formulation cis-[Pt(NH₃)₂(Am)Cl]NO₃ (where Am represents a substituted pyridine). The order of reaction rate of the reactions was found to be: 3-phpy > 4-phpy > py > 4-mepy > 3-mepy > 2-mepy. The two basic factors, steric and electronic, were attributed to the order of the binding rate constants. A possible mechanism of the reaction of cis-[Pt(NH₃)₂(Am)Cl]⁺ with 5′-GMP suggested that the reactions proceed via direct nucleophilic attack and no loss of ammonia. cis-[Pt(NH₃)₂(Am)Cl]⁺ binds to the N7 nitrogen of the guanine residue of 5′-GMP to form a coordinate bond with the Pt metal centre. This mechanism is apparently different from that of cisplatin. The pK_a value of cis-[Pt(NH₃)₂(4-mepy)(H₂O)](NO₃)₂ (5.63) has been determined at 298 K by the use of distortionless enhancement by polarization transfer (DEPT) ¹⁵N NMR spectroscopy and compared to the pK_a value of cis-[PtCl(H₂O)(NH₃)₂]⁺.     

Effect of thiol-functionalised silica on cisplatin adsorption

This study contributes to the investigation related to guest–host interactions between the chemotherapeutic agent cisplatin and a functionalised silica matrix in order to improve and find new materials such as drug carriers. The adsorption of cisplatin and its complexes, cis-[PtCl(NH₃)₂]⁺ and cis-[Pt(NH₃)₂]²⁺, on a SH-functionalised SiO₂(111) surface has been studied by the atom superposition and electron delocalisation method. The adiabatic energy curves for the adsorption of the drug and its products on the delivery system were considered. The electronic structure and bonding analysis were also performed. The molecule and their complex are adsorbed on the functionalised surface resulting in a major absorption of the cis-[Pt(NH₃)₂]²⁺ complex. The molecule–surface interactions are formed via –SH group. The molecule/complexes SH electron-donating effect plays an important role in the catalytic reaction. The more important drug–carrier interactions occur through the Cl–H bond for the adsorption of cis-[PtCl₂(NH₃)₂] and cis-[PtCl(NH₃)₂]⁺, and through the Pt–S and Pt–H interactions for cis-[Pt(NH₃)₂]²⁺ adsorption. When the new interactions are formed, the functionalised carrier maintains their matrix properties while the molecule is the most affected after adsorption. The Pt atomic orbitals present the most important changes during adsorption.     

The ruthenium complexes cis-(dichloro)tetramineruthenium(III) chloride and cis-tetraammine(oxalato)ruthenium(III) dithionate overcome resistance inducing apoptosis on human lung carcinoma cells (A549)

Lung cancer is one of the leading causes of death in the world, and non-small cell lung carcinoma accounts for approximately 75–85 % of all lung cancers. In the present work, we studied the antitumor activity of the compound cis-(dichloro)tetramineruthenium(III) chloride {cis-[RuCl₂(NH₃)₄]Cl} against human lung carcinoma tumor cell line A549. The present study aimed to investigate the relationship between the expression of MDR1 and CYP450 genes in human lung carcinoma cell lines A549 treated with cisCarboPt, cisCRu(III) and cisDRu(III). The ruthenium-based coordinated complexes presented low cytotoxic and antiproliferative activities, with high IC₅₀ values, 196 (±15.49), 472 (±20.29) and 175 (±1.41) for cisCarboPt, cisCRu(III) and cisDRu(III), respectively. The tested compounds induced apoptosis in A549 tumor cells as evidenced by caspase 3 activation, but only at high concentrations. Results also revealed that the amplification of P-gp gene is greater in A549 cells exposed to cisCarboPt and cisCRu(III) than cisDRu(III). Taken together all these results strongly demonstrate that MDR-1 over-expression in A549 cells could be associated to a MDR phenotype of these cells and moreover, it is also contributing to the platinum, and structurally-related compound, resistance in these cells. The identification and characterization of novel mechanisms of drug resistance will enable the development of a new generation of anti-cancer drugs that increase cancer sensitivity and/or represent more effective chemotherapeutic agents.     

Versatile coordination behaviour of Ph2AsCH2AsPh2 with Ru(II)

Treatment of ‘RuCl₃ · 3H₂O’ with Ph₂AsCH₂AsPh₂ (dpam) in hot EtOH gives either trans-[RuCl₂(dpam-As,As′)(dpam-As)₂] (1), or cis-[RuCl₂(dpam-As,As′)₂] (2), depending on the mole ratio. On exposure to light, solutions of 2 isomerise to trans-[RuCl₂(dpam-As,As′)₂] (3). Treatment of [RuCl₂(PPh₃)₃] with two equivalents of dpam in CH₂Cl₂ gave a mixture of two products, from which trans-[RuCl₂(PPh₃) (dpam-As,As′)(dpam-As)] (4) was isolated by recrystallisation. The crystal structures of 1-4 are reported. Complexes 1-3 in CH₂Cl₂ undergo electrochemical oxidation to Ru(III), and the Ru(III) form of 2 undergoes isomerisation on the voltammetric timescale to the Ru(III) form of 3.     

Oligophosphine ligands. XIII. Halo and hydro complexes of ruthenium(II) containing the novel tripod tetrakis(tertiary) phosphine P(CH2CH2CH2PMe2)3

The reaction of the ruthenium complexes RuCl₂(PPh₃)₃, RuCl₂(PPh₃)₄, RuCl₂(PMe₃)₄, RuCl₂(Me₂SO)₄, or RuBr₂(PPh₃)₃ with the tripod tetrakis(tertiary) phosphine P(CH₂CH₂CH₂PMe₂)₃ gave the compounds cis-RuCl₂ [P(CH₂CH₂CH₂PMe₂)₃] (1) and cis-RuBr₂[P(CH₂CH₂CH₂PMe₂)₃] (2). The coordination geometry of 1 and 2 was derived from the ABX₂ type ³¹P NMR patterns of the complexes, as well as from an X-ray structure determination for the chloride 1. Crystals of 1 were found to be monoclinic, space group P2₁/n (Z = 4), with a = 942.0(3), b = 1446.2(4), c = 1680(1) pm, and β = 104.99(4)°. Anisotropic refinement of the structure converged at R = 0.040 and R_w = 0.034 (3318 data). Selected bond lengths are (in pm): RuP(CH₂−)Me₂ (trans-atom P), 235.8(1) and 239.3(1); RuP(CH₂−)Me₂ (trans-atom Cl), 227.9(1); RuP(CH₂−)₃, 225.3(1); RuCl (trans-group P(CH₂−)₃), 252.1(1); and RuCl (trans-group P(CH₂)Me₂), 250.5(1). Reaction of 1 with LiAlH₄ yielded the hydro derivatives cis-Ru(H)Cl[P(CH₂CH₂CH₂PMe₂)₃] (3) and cis-RuH₂[P(CH₂CH₂CH₂PMe₂)₃] (4), which were characterized by IR and ¹H and ³¹p NMR spectroscopy.     

Coordination chemistry of Re complexes with 2(2′-pyridyl)benzimidazole

Two new Re(III) and Re(IV) complexes with 2(2′-pyridyl)benzimidazole (pbimz) were prepared and their crystal and molecular structures established by single-crystal X-ray diffraction. Reaction of [ReOCl₂(OEt)(PPh₃)₂] with the ligand gave red cis(Cl),trans(P)-[ReCl₂(PPh₃)₂(pbimz)]Cl (1), while red [ReCl₄(pbimz)] · OPPh₃ (2) was obtained from [ReCl₃(PhC(O)C(O)Ph)(PPh₃)] and pbimz in the presence of perchlorate. The compounds were characterized by elemental analysis, FAB-MS, UV-Vis, IR, NMR spectroscopy and magnetic susceptibility measurements.     

Elimination of Col E1 (pBR322 and pBR329) plasmids inEscherichia coli on treatment with hexammine ruthenium(III) chloride

Hexammine ruthenium(III) chloride, (Ru[NH₃]6)Cl₃, a potent novel compound, eliminated 100% of pBR322 and pBR329 plasmids fromEscherichia coli, rendering the bacteria vulnerable to the antibiotic-resistance markers carried on these plasmids. However, the curing activity of hexammine ruthenium(III) chloride was pH dependent.     

Investigations into the interaction between tumor-inhibiting ruthenium(III) complexes and nucleotides by capillary electrophoresis

Ruthenium(III) complexes of the general formula HL[RuCl₄L₂], with two trans-standing heterocyclic ligands L bound to ruthenium via nitrogen, show remarkable activity in different tumor models. To obtain a deeper insight into the mode of action of this class of anticancer compounds, we investigated the interaction of HIm trans-[RuCl₄(im)₂] (im, imidazole) and HInd trans-[RuCl₄(ind)₂] (ind, indazole) with all four nucleoside monophosphates in buffered solution by means of capillary electrophoresis. A preference for GMP- and AMP-coordination was found. A decrease of the pH resulted in a significantly increased amount of bound nucleotide. This feature seems to be interesting with regard to the lower pH values in solid tumors.     

Photoproducts from the photolysis of tris(bipyridine)ruthenium(II) chloride in dimethylformamide

Six photoproducts were observed in the photolysis of [Ru(bpy)₃]²⁺ in N,N-dimethylformamide (DMF) in the presence of chloride ions. The primary products were cis-[Ru(bpy)₂Cl₂] and cis-[Ru(bpy)₂-(DMF)Cl]⁺. The remaining ruthenium products, which were thermally unstable to varying degrees, were cis-[Ru(bpy)₂Cl₂]⁺, [Ru(bpy)₃]⁺, and a binuclear species we have tentatively identified as [Ru(bpy)₂Cl]₂ⁿ⁺ (n = 3 or 4).     

Transition metal complexes with sulfur ligands. XXVIII. Ruthenium complexes of the pentadentate thioether thiolate ligands dpttd (2,3,11,12-dibenzo-1,4,7,10,13-pentathiatridecane(−2)) and the sterically demanding derivative bu4-dpttd (14,16,18,20-tetra (t-butyl)-2,3,11,12-dibenzo-1,4,7,10,13-pentathiatridecane(−2))

The template alkylation of Li₂[Ru(CO)₂(S₂C₆H₄)₂] (S₂C₆H₄²⁻ = 1,2-benzenedithiolate(−2)) by S(C₂H₄Br)₂ yields [Ru(CO)₂(dpttd)] (dpttd²⁻ = 3,11,12-dibenzo-1,4,7,10,13-pentathiatridecane(−2)) which is thermally converted into the monocarbonyl complex [Ru(CO)(dpttd)]. The reactions of dpttd-H₂ or dpttd²⁻ with [RuCl₂(PPh₃)₃], [RuCl₂(DMSO)₄], [RuCl₃(PhSCH₃)₃] and RuCl₃(NO)·xH₂O lead to [Ru(L)(dpttd)] and [Ru(L)(dpttd)]Cl (L = PPh₃, DMSO, PhSCH₃, NO), respectively, which are practically insoluble in all common solvents. Better soluble complexes are obtained with the new sterically demanding ligand ^tbu₄-dpttd²⁻ = 14,16,18,20-tetra(t-butyl)-2,3,11,12-dibenzo-1,4,7, 10,13-pentathiatridecane(−2); it is obtained in isomerically pure form by the reaction of tetrabuthylammonium-3,5-di (t-butyl)-1,2-benzenethiolthiolate, NBu₄[^tbu₂-C₆H₂S(SH), with S(C₂H₄Br)₂ and yields on reaction with [RuCl₂(PPh₃)₃] the very soluble [Ru(PPh₃)₂(^tbu₄-dpttd)] as well as [Ru(PPh₃(^tbu₄-dpttd)]. The ¹H NMR and ³¹P NMR spectra indicate that in solution [Ru(PPh₃)₂(^tbu₄-dpttd)] exists as a mixture of diastereomers, whereas [Ru(PPh₃)(^tbu₄-dpttd)] forms one pair of enantiomers only. This was confirmed by an X-ray structure determination of a single crystal. [Ru(PPh₃)(^tbu₄-dpttd)] crystallizes in space group P2₁/n with a = 10.496(4), b = 14.888(6), c = 32.382(12) Å, β = 98.04(3)°, Z = 4 and D_calc. = 1.27 g/cm³, R = 4.84; R_W = 5.06%; the ruthenium center is coordinated pseudooctahedrally by one phosphorus, two thiolate and three thiother S atoms.     

Synthesis and structures of platinum(II) complexes with 5-ferrocenylpyrimidine

Reaction of platinum(II) salts with 5-ferrocenylpyrimidine (FcPM) afforded cis-[Pt(NH₃)₂(FcPM)₂](PF₆)₂ (1), trans-[Pt(NH₃)₂(FcPM)₂](PF₆)₂ (2), cis-[PtCl₂(FcPM)₂] (3), and cis-[PtCl₂(DMSO)(FcPM)] (4): their spectroscopic and electrochemical properties were investigated. Complexes 1 and 2 were structurally characterized by X-ray crystallography.     

Copper-thioarylazoimidazole complexes: Structures, photochromism and redox interconversion between Cu(II) ↔ Cu(I) and correlation with DFT calculation

Reaction of Cu(ClO₄)₂·6H₂O, SRaaiNR′ (1-alkyl-2-[(o-thioalkyl)phenylazo]imidazole) and NH₄SCN (1:1:2 mol ratio) affords distorted square pyramidal, [Cu^II(SRaaiNR′)(SCN)₂] (3) compound while identical reaction with [Cu(MeCN)₄](ClO₄) yields -SCN- bridged coordination polymer, [Cu^I(SRaaiNR′)(SCN)]_n (4). These two redox states [Cu^II and Cu^I] are interconvertible; reduction of [Cu^II(SRaaiNR′)(SCN)₂] by ascorbic acid yields [Cu^I(SRaaiNR′)(SCN)]_n while the oxidation of [Cu^I(SRaaiNR′)(SCN)]_n by H₂O₂ in presence of excess NH₄SCN affords [Cu^II(SRaaiNR′)(SCN)₂]. They are structurally confirmed by single crystal X-ray diffraction study. Cyclic voltammogram of the complexes show Cu(II)/Cu(I) redox couple at ∼0.4 V and azo reductions at negative to SCE. UV light irradiation in MeCN solution of [Cu^I(SRaaiNR′)(SCN)]_n (4) show trans-to-cis isomerisation of coordinated azoimidazole. The reverse transformation, cis-to-trans, is very slow with visible light irradiation while the process is thermally accessible. Quantum yields (?_t→c) of trans-to-cis isomerisation are calculated and free ligands show higher ? than their Cu(I) complexes. The activation energy (E_a) of cis-to-trans isomerisation is calculated by controlled temperature experiment. Copper(II) complexes, 3, do not show photochromism. DFT and TDDFT calculation of representative complexes have been used to determine the composition and energy of molecular levels and results have been used to explain the solution spectra, photochromism and redox properties of the complexes.     

The structure of a platinum(II) complex of cytidine-3'-monophosphate.

The structure of the cis-[Pt(NH₃)₂(3′-CMP)₂]^2? ion, isolated in a partially protonated form as its cesium salt, has been analyzed by single-crystal x-ray diffraction methods. The 3′-CMP ligands bind in a monodentate fashion through their N(3) atoms: in contrast to the structure of [Pt(en)(5′-CMP)]₂, no covalent platinum-phosphate bonding is found. This compound represents the first example of a 1:2 cis-metal/cytosine complex structurally characterized.     

Synthesis and spectroscopic properties of some new seven-coordinate thioacetamide complexes of molybdenum(II) and tungsten(II)

The compounds [MI₂(CO)₃(NCMe)₂] (M = Mo or W) react with one equivalent of SC(NH₂)Me in CH₂Cl₂ at room temperature to initially give the acetonitrile substituted products [MI₂(CO)₃(NCMe)- {SC(NH₂)Me}] which was isolated for M = W. However, the molybdenum complex rapidly dimerizes with loss of acetonitrile to give the iodide-bridged compound [Mo(σ-I)I(CO)₃ {SC(NH₂)Me}]₂. The tungsten complex does not appear to dimerize, even after stirring at room temperature for 72 h in CH₂Cl₂. Two equivalents of thioacetamide react with [MI₂- (CO)₃(NCMe)₂] in CH₂Cl₂ at room temperature to give the new bisthioacetamide compounds [MI₂- (CO)₃{SC(NH₂)Me}₂] via displacement of the labile acetonitrile ligands. The low temperature (−70 °C) ¹³C NMR spectrum of [WI₂(CO)₃{SC(NH₂)Me}₂] indicates that the geometry of the complex is capped octahedral with a carbonyl ligand in the unique capping position.